Key Industry Issues Dealt with at BioTrinity

The UK's Premier Biotech and Investment conference will feature plenaries and panel discussions from the successful entrpreneurs John Burt, David Knowles and Ken Powell who built up and sold UK biotechnology companies Thiakis, Piramed and Arrow and returned nearly $500m of value to their investors.

BioTrinity 2009 will face the challenges of the current climate head-on with key issues addressed by industry leaders. Dealing with successful deal making in the current climate, BioTrinity will draw on the experiences of key industry pharma licensing figures, including Nigel Sheail, VP Global Head of Licensing, Roche, Esteban Pombo-Villar, Head of Strategic Alliance Management, Novartis Institutes of BioMedical Research and Kate Burt, Director, Transactions, GSK.

Dealing with successful fundraising in the current climate, BioTrinity will draw on the experiences of key VCs including Regina Hodits, Partner at Atlas Venture, which recently closed its $283m Fund VIII, as well as corporate venturers Graeme R Martin, CEO, Takeda Research Investments, Martin Edwards, Senior Partner, Novo A/S, Allison Robbins, Senior Associate, Genzyme Ventures, Sam Fazelli, Head of European Equity Research, Piper Jaffray and David Mott, Investment Director at Oxford Capital Partners who will be among over 50 investor delegates expected to attend this year.

There are just a few days left to register at the Special Rate, and you will be able to start requesting meetings when the partnering meeting is activated in a few days time.

Download the BioTrinity 2009 - Preliminary Programme - Now Available!

Who else is attending BioTrinity 2009?

 

WHO SHOULD ATTEND?

Biotech & MedTech Executives

• 8 minute presentation opportunity to pharma and investor audience
• Panel discussions for emerging biotechs on finance and key issues
• Private 1-to-1 partnering rooms and booths

Mid & Large Pharma Executives

• Access to Company presentations (Biotech and Medtech)
• Private 1-to-1 partnering rooms and booths
• Opportunity for dedicated partnering rooms

Investors

• Invitation-only investor dinner
• Wide range of investment opportunities
• Private 1-to-1 partnering rooms
• Opportunity for dedicated partnering rooms